Has come back (relapsed) within a year of treatment or does not go away (refractory) after your first treatment Has relapsed or is refractory and you cannot receive a hematopoietic stem cell ...

The trial includes dose-escalation and dose-expansion segments.

B-cell lymphomas represent a heterogeneous group of neoplasms originating from B lymphocytes, with variable clinical behaviour and prognostic outcomes. Extranodal involvement occurs when these ...

The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...

Metabolic tumor volume—a biomarker derived from PET imaging—can more accurately predict progression-free survival for large B ...

B-cell lymphomas represent a diverse group of malignancies arising from B lymphocytes, among which diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma are particularly prevalent. Recent ...

Germinal center B-cell–like diffuse large B-cell lymphomas (GCB-DLBCLs) show dependence on DOT1L and EZH2, with combined targeting offering potential as an alternative differentiation-based therapy.

Researchers assessed whether using bispecific antibodies targeting CD20 and CD3 would reduce efficacy or increase toxicity in patients with relapsed or refractory non-Hodgkin B-cell lymphomas ...

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester ...

CD20 expression levels correlate with outcomes in B-cell lymphoma patients treated with CD20xCD3 bispecific antibodies. Patients with reduced CD20 expression had significantly lower PFS and OS rates ...